Beta Bionics (NASDAQ:BBNX - Get Free Report)'s stock had its "sell (d)" rating reiterated by equities research analysts at Weiss Ratings in a research report issued on Friday,Weiss Ratings reports.
Other analysts have also recently issued reports about the stock. Robert W. Baird set a $17.00 target price on shares of Beta Bionics and gave the stock a "neutral" rating in a research note on Wednesday, July 30th. Stifel Nicolaus initiated coverage on shares of Beta Bionics in a research note on Tuesday. They issued a "buy" rating and a $26.00 target price on the stock. Truist Financial increased their target price on shares of Beta Bionics from $21.00 to $28.00 and gave the stock a "buy" rating in a research note on Monday, September 22nd. Finally, The Goldman Sachs Group set a $26.00 target price on shares of Beta Bionics and gave the stock a "buy" rating in a research note on Wednesday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $24.56.
View Our Latest Analysis on Beta Bionics
Beta Bionics Stock Performance
NASDAQ BBNX traded up $0.95 on Friday, hitting $20.96. The stock had a trading volume of 904,188 shares, compared to its average volume of 593,813. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $26.66. The firm has a 50-day moving average of $20.85 and a 200-day moving average of $16.59.
Beta Bionics (NASDAQ:BBNX - Get Free Report) last posted its earnings results on Tuesday, July 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.51) by $0.12. The firm had revenue of $23.24 million during the quarter, compared to analysts' expectations of $19.73 million. Beta Bionics has set its FY 2025 guidance at EPS.
Insiders Place Their Bets
In other Beta Bionics news, CFO Stephen Feider sold 4,982 shares of the firm's stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $21.69, for a total value of $108,059.58. Following the sale, the chief financial officer owned 44,041 shares of the company's stock, valued at $955,249.29. This trade represents a 10.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Mark Hopman sold 11,411 shares of the firm's stock in a transaction on Friday, September 5th. The stock was sold at an average price of $20.56, for a total transaction of $234,610.16. Following the completion of the sale, the insider directly owned 31,215 shares in the company, valued at approximately $641,780.40. This trade represents a 26.77% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 68,901 shares of company stock worth $1,314,543.
Institutional Investors Weigh In On Beta Bionics
A number of large investors have recently modified their holdings of BBNX. Strs Ohio purchased a new position in shares of Beta Bionics in the first quarter worth $29,000. CWM LLC purchased a new stake in shares of Beta Bionics during the second quarter valued at $58,000. Legal & General Group Plc boosted its position in shares of Beta Bionics by 197.4% during the second quarter. Legal & General Group Plc now owns 3,976 shares of the company's stock valued at $58,000 after buying an additional 2,639 shares during the last quarter. Corebridge Financial Inc. purchased a new stake in shares of Beta Bionics during the first quarter valued at $79,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Beta Bionics during the first quarter valued at $95,000.
About Beta Bionics
(
Get Free Report)
Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Beta Bionics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Beta Bionics wasn't on the list.
While Beta Bionics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
